BR

BrightPath Biotherapeutics Co., Ltd.

A clinical-stage biopharma company developing cancer immunotherapies and cell therapies.

4594 | T

Overview

Corporate Details

ISIN(s):
JP3274140007
LEI:
Country:
Japan
Address:
川崎市川崎区殿町三丁目25番22号

Description

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's core technology is its iPS-NKT platform, a novel allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to produce large, homogeneous quantities of natural killer T (NKT) cells for cancer treatment. This proprietary approach is designed to overcome the natural scarcity of NKT cells, enabling the therapeutic application of their multifaceted anti-tumor effects. In addition to its cell therapy program, the company's development pipeline includes cancer peptide vaccines and immuno-modulating antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 07:30
有価証券届出書(組込方式)
Japanese 241.2 KB
2025-11-14 07:34
確認書
Japanese 8.9 KB
2025-11-14 07:34
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 198.0 KB
2025-06-20 09:01
臨時報告書
Japanese 22.8 KB
2025-06-19 08:36
確認書
Japanese 8.9 KB
2025-06-19 08:32
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 23.4 KB
2025-06-19 08:25
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 933.5 KB
2024-11-08 07:35
確認書
Japanese 9.0 KB
2024-11-08 07:34
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 224.9 KB
2024-06-21 09:07
訂正有価証券届出書(組込方式)
Japanese 254.0 KB
2024-06-21 08:34
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 23.2 KB
2024-06-21 08:33
確認書
Japanese 9.0 KB
2024-06-21 08:32
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 990.5 KB
2024-06-19 08:00
有価証券届出書(組込方式)
Japanese 513.9 KB
2024-02-09 07:12
確認書
Japanese 9.1 KB

Automate Your Workflow. Get a real-time feed of all BrightPath Biotherapeutics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BrightPath Biotherapeutics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BrightPath Biotherapeutics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advicenne Logo
A specialty pharmaceutical company developing treatments for rare renal diseases.
France
ALDVI
AegirBio AB Logo
A diagnostics company specializing in therapeutic drug monitoring for biological drugs.
Sweden
AEGIR
Aelis Farma Logo
Biopharmaceutical company developing CB1 receptor inhibitors for CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Clinical-stage company developing therapeutic applications for botulinum toxins.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics with integrated R&D and manufacturing.
Japan
2927
AGENUS INC Logo
A clinical-stage biotechnology company specializing in immuno-oncology therapies.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Biopharmaceutical company developing therapies for rare and genetically defined diseases.
United States of America
AGIO
AHN-GOOK PHARMACEUTICAL Co., Ltd. Logo
Develops and markets medicines, focusing on respiratory and cardiovascular treatments.
South Korea
001540
Akari Therapeutics Plc Logo
Develops next-gen antibody-drug conjugates using proprietary cancer-killing toxins.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
A biopharmaceutical company that develops and commercializes therapeutics for kidney disease.
United States of America
AKBA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.